Katya Ascher - McDermott Will & Emery


Katya Ascher focuses her practice on patent law issues in litigation and transactional matters across technology sectors. She has over 15 years of experience counseling clients in the United States, France, and the United Kingdom. Her clients include mid-sized companies and start-ups, operating in the biotechnology, pharmaceutical, medical device, nutraceutical, veterinary and engineering fields.

She regularly negotiates every type of agreement associated with research and development, technology transfer, services, manufacturing and distribution.

She also represents French companies in patent litigation and contractual disputes in the US, handling all facets of pre-suit matters, pretrial discovery, case management and trial preparations.

Katya Ascher spent the first five years of her career as an associate in one of the top New York intellectual property boutiques where she litigated cases in district court and the International Trade Commission and advised clients on patent validity and infringement. Before studying law, Katya gained technical experience as an intern in a genomic research laboratory of a major biotechnology company.


  • Counsel for Seppic Inc. and Activ’Inside SA in an ongoing patent infringement and false advertisement action (Seppic, Inc. v Pharmacive Biotech Products SLU (D.N.J))
  • Advised Pierre Fabre on its exclusive collaboration and license agreement with Scorpion Therapeutics, Inc. for the co-development of certain epidermal growth factor receptor inhibitors
  • Advised Innate Pharma SA on an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates with a primary focus in Celiac disease
  • Advised Corteria Pharmaceuticals on an exclusive license agreement with Sanofi SA in respect of two cardiovascular assets designed to treat some types of heart failure
  • Advised Dynacure on an agreement granting Nippon Shinyaku Co., Ltd. the exclusive option to acquire development and commercial rights in Japan to develop and commercialize DYN101, an investigational antisense oligonucleotide product candidate for treatment of Myotubular and Centronuclear Myopathies

Show More


  • The Best Lawyers in France, “Ones to Watch” in Biotechnology & Life Sciences, 2024
  • Legal 500 EMEA, Recommended Lawyer, 2022


University of Paris II Panthéon-Assas, Master 2 Industrial Property, 2012
University of North Carolina School of Law, JD, with honors, 2005
University of North Carolina at Chapel Hill, BA, Biology, with distinction, 2002

Show More